• Einstein and Montefiore Researchers Awarded $7.6 Million in NIH Grants to Study Depression in People Living with HIV - (11/22/21)
   
  
• "I'm Just Forgetting and I Don't Know Why": Exploring How People Living With HIV-Associated Neurocognitive Disorder View, Manage, and Obtain Support for Their Cognitive Difficulties - (11/21/21)
   
  
• High-Dose Marine Omega-3s Raise Risk for Atrial Fibrillation - (11/19/21)
   
  
• The Esperanza Patient: More Hope for a Sterilizing HIV-1 Cure: A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation - (11/17/21)
   
  
• AASLD: INSTIs and DAAs Boost Liver Transplant Survival in HIV+ and HIV+/HCV+ in US - (11/16/21)
   
  
• AASLD: Simple Tool Tells Primary Care Docs When to Refer People With NAFLD - Mark Mascolini - (11/15/21)
   
  
• AASLD: HIV is independently associated with elevated FibroScan-AST (FAST) score, a non-invasive measurement of non-alcoholic steatohepatitis with significant activity and fibrosis - Mark Mascolini - (11/15/21)
   
  
• AASLD: Simple Tool Tells Primary Care Docs When to Refer People With NAFLD - Mark Mascolini - (11/15/21)
   
  
• AASLD: HIV is independently associated with elevated FibroScan-AST (FAST) score, a non-invasive measurement of non-alcoholic steatohepatitis with significant activity and fibrosis - Mark Mascolini - (11/15/21)
   
  
• Weight Change in NEAT-022, Switch to dolutegravir from boosted PI, 96 weeks at Glasgow 2018 - (11/11/21)
   
  
• No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV - (11/10/21)
   
  
• No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults - (11/10/21)
   
  
• EACS: Efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in patients with pre-existing nrti resistances: real world data - (11/10/21)
   
  
• EACS: Integrase inhibitor drug resistance in clinical practice in the United Kingdom - (11/10/21)
   
  
• Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults - (11/08/21)
   
  
More HIV Articles...
 

More News Updates Articles...
 

• EASL: HCV Micro-Elimination Funding Grants Available
   
  
• EASL: Summary from EASL 2021 for Hepatitis B, C, D and fatty liver disease. Liver disease in 2021: advances and remaining challenges. Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (07/25/21)
   
  
• Point-of-care HCV RNA testing with peer-led and nurse-based support to enhance HCV treatment among people with recent injecting drug use at a community-led needle and syringe program: the TEMPO pilot study - see study results below - (11/22/21)
   
  
More Hep C Articles...
 

• AASLD: Preliminary Results From a Phase 2 Study Evaluating VIR-2218 Alone and in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis B Infection (11/23/21)
   
  
• AASLD: ARO-HSD, an investigational RNAi therapeutic, demonstrates reduction in ALT and hepatic HSD17B13 mRNA and protein in patients with NASH or suspected NASH (11/23/21)
   
  
• AASLD: Rapid HBsAg Reduction in Chronic Hepatitis B Virus Infection: Preliminary Results From a Phase 1 Study Evaluating a Single Dose of VIR-3434, a Novel Neutralizing, Vaccinal Monoclonal Antibody (11/23/21)
   
  
• AASLD: Understanding Patient Experiences with Chronic Hepatitis B Virus and its Treatments (11/23/21)
   
  
• AASLD: Changes in Viral Antigens are More Strongly Associated with HBV pgRNA than HBV DNA in Studies of Vebicorvir and NrtI in Treatment-naïve Patients with Chronic HBV Infection (11/23/21)
   
  
• AASLD: EFFICACY OF LONG-TERM TREATMENT OF CHRONIC HEPATITIS D PATIENTS WITH BULEVIRTIDE - RESULTS OF A "REAL WORLD" STUDY (11/23/21)
   
  
• AASLD: TREATMENT WITH BEPIROVIRSEN (GSK3228836) LEADS TO HEPATITIS B SURFACE ANTIGEN (HBsAg) REDUCTION AND CYTOKINE/ CHEMOKINE RESPONSES LINKED TO INNATE AND ADAPTIVE IMMUNITY IN A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (11/23/21)
   
  
• AASLD: Amino Acid Substitutions in the Inhibitor Binding Pocket of HBV Core Protein Confer Differential Changes in Susceptibility to Three Generations of HBV Core Inhibitors (11/23/21)
   
  
• AASLD: Analysis of the longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open-label extension study (11/23/21)
   
  
• AASLD: Persistently detectable serum HBV DNA and pgRNA is associated with subsequent hepatocellular carcinoma development in chronic hepatitis B patients receiving chronic NRTI treatment (11/23/21)
   
  
More Hep B Articles...
 

List not necessarily listed here in order of date being held.